The remarkable therapeutic effect of T-DM1 combined with osimertinib in EGFR-mutated or HER2-overexpressing NSCLC cell lines was shown by Silvia La Monica et al. and validated by several other researchers over the years. Here, ERBB2 is linked to non-small cell lung carcinoma.